- Home
- DBD vs VCYT Comparison
DBD vs VCYT Comparison
Compare DBD & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBD | VCYT |
|---|---|---|
| Founded | 1859 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2023 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DBD | VCYT |
|---|---|---|
| Price | $77.77 | $32.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $90.00 | $44.33 |
| AVG Volume (30 Days) | 202.7K | ★ 847.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | 164.52 |
| EPS | ★ 2.54 | 0.82 |
| Revenue | ★ $3,805,700,000.00 | N/A |
| Revenue This Year | $3.56 | $13.48 |
| Revenue Next Year | $3.25 | $12.67 |
| P/E Ratio | ★ $30.59 | $39.60 |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $34.88 | $22.61 |
| 52 Week High | $84.46 | $50.71 |
Technical Indicators
Market Signals| Indicator | DBD | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 44.23 |
| Support Level | $71.24 | $31.22 |
| Resistance Level | $80.10 | $33.95 |
| Average True Range (ATR) | 2.35 | 1.37 |
| MACD | 0.24 | 0.13 |
| Stochastic Oscillator | 72.36 | 55.98 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).